Copyright Reports & Markets. All rights reserved.

Global Genetic Virus Vector Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Genetic Virus Vector Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Retroviral Vectors
    • 1.2.3 Adenoviral Vectors
    • 1.2.4 Adeno-Associated Viral Vectors
    • 1.2.5 Other
  • 1.3 Market by Application
    • 1.3.1 Global Genetic Virus Vector Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Gene Therapy
    • 1.3.3 Vaccinology
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Genetic Virus Vector Market Perspective (2016-2027)
  • 2.2 Genetic Virus Vector Growth Trends by Regions
    • 2.2.1 Genetic Virus Vector Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Genetic Virus Vector Historic Market Share by Regions (2016-2021)
    • 2.2.3 Genetic Virus Vector Forecasted Market Size by Regions (2022-2027)
  • 2.3 Genetic Virus Vector Industry Dynamic
    • 2.3.1 Genetic Virus Vector Market Trends
    • 2.3.2 Genetic Virus Vector Market Drivers
    • 2.3.3 Genetic Virus Vector Market Challenges
    • 2.3.4 Genetic Virus Vector Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Genetic Virus Vector Players by Revenue
    • 3.1.1 Global Top Genetic Virus Vector Players by Revenue (2016-2021)
    • 3.1.2 Global Genetic Virus Vector Revenue Market Share by Players (2016-2021)
  • 3.2 Global Genetic Virus Vector Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Genetic Virus Vector Revenue
  • 3.4 Global Genetic Virus Vector Market Concentration Ratio
    • 3.4.1 Global Genetic Virus Vector Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Genetic Virus Vector Revenue in 2020
  • 3.5 Genetic Virus Vector Key Players Head office and Area Served
  • 3.6 Key Players Genetic Virus Vector Product Solution and Service
  • 3.7 Date of Enter into Genetic Virus Vector Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Genetic Virus Vector Breakdown Data by Type

  • 4.1 Global Genetic Virus Vector Historic Market Size by Type (2016-2021)
  • 4.2 Global Genetic Virus Vector Forecasted Market Size by Type (2022-2027)

5 Genetic Virus Vector Breakdown Data by Application

  • 5.1 Global Genetic Virus Vector Historic Market Size by Application (2016-2021)
  • 5.2 Global Genetic Virus Vector Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Genetic Virus Vector Market Size (2016-2027)
  • 6.2 North America Genetic Virus Vector Market Size by Type
    • 6.2.1 North America Genetic Virus Vector Market Size by Type (2016-2021)
    • 6.2.2 North America Genetic Virus Vector Market Size by Type (2022-2027)
    • 6.2.3 North America Genetic Virus Vector Market Size by Type (2016-2027)
  • 6.3 North America Genetic Virus Vector Market Size by Application
    • 6.3.1 North America Genetic Virus Vector Market Size by Application (2016-2021)
    • 6.3.2 North America Genetic Virus Vector Market Size by Application (2022-2027)
    • 6.3.3 North America Genetic Virus Vector Market Size by Application (2016-2027)
  • 6.4 North America Genetic Virus Vector Market Size by Country
    • 6.4.1 North America Genetic Virus Vector Market Size by Country (2016-2021)
    • 6.4.2 North America Genetic Virus Vector Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Genetic Virus Vector Market Size (2016-2027)
  • 7.2 Europe Genetic Virus Vector Market Size by Type
    • 7.2.1 Europe Genetic Virus Vector Market Size by Type (2016-2021)
    • 7.2.2 Europe Genetic Virus Vector Market Size by Type (2022-2027)
    • 7.2.3 Europe Genetic Virus Vector Market Size by Type (2016-2027)
  • 7.3 Europe Genetic Virus Vector Market Size by Application
    • 7.3.1 Europe Genetic Virus Vector Market Size by Application (2016-2021)
    • 7.3.2 Europe Genetic Virus Vector Market Size by Application (2022-2027)
    • 7.3.3 Europe Genetic Virus Vector Market Size by Application (2016-2027)
  • 7.4 Europe Genetic Virus Vector Market Size by Country
    • 7.4.1 Europe Genetic Virus Vector Market Size by Country (2016-2021)
    • 7.4.2 Europe Genetic Virus Vector Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Genetic Virus Vector Market Size (2016-2027)
  • 8.2 Asia-Pacific Genetic Virus Vector Market Size by Type
    • 8.2.1 Asia-Pacific Genetic Virus Vector Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Genetic Virus Vector Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Genetic Virus Vector Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Genetic Virus Vector Market Size by Application
    • 8.3.1 Asia-Pacific Genetic Virus Vector Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Genetic Virus Vector Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Genetic Virus Vector Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Genetic Virus Vector Market Size by Region
    • 8.4.1 Asia-Pacific Genetic Virus Vector Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Genetic Virus Vector Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Genetic Virus Vector Market Size (2016-2027)
  • 9.2 Latin America Genetic Virus Vector Market Size by Type
    • 9.2.1 Latin America Genetic Virus Vector Market Size by Type (2016-2021)
    • 9.2.2 Latin America Genetic Virus Vector Market Size by Type (2022-2027)
    • 9.2.3 Latin America Genetic Virus Vector Market Size by Type (2016-2027)
  • 9.3 Latin America Genetic Virus Vector Market Size by Application
    • 9.3.1 Latin America Genetic Virus Vector Market Size by Application (2016-2021)
    • 9.3.2 Latin America Genetic Virus Vector Market Size by Application (2022-2027)
    • 9.3.3 Latin America Genetic Virus Vector Market Size by Application (2016-2027)
  • 9.4 Latin America Genetic Virus Vector Market Size by Country
    • 9.4.1 Latin America Genetic Virus Vector Market Size by Country (2016-2021)
    • 9.4.2 Latin America Genetic Virus Vector Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Genetic Virus Vector Market Size (2016-2027)
  • 10.2 Middle East & Africa Genetic Virus Vector Market Size by Type
    • 10.2.1 Middle East & Africa Genetic Virus Vector Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Genetic Virus Vector Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Genetic Virus Vector Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Genetic Virus Vector Market Size by Application
    • 10.3.1 Middle East & Africa Genetic Virus Vector Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Genetic Virus Vector Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Genetic Virus Vector Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Genetic Virus Vector Market Size by Country
    • 10.4.1 Middle East & Africa Genetic Virus Vector Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Genetic Virus Vector Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 FUJIFILM Diosynth Biotechnologies U.S.A.
    • 11.1.1 FUJIFILM Diosynth Biotechnologies U.S.A. Company Details
    • 11.1.2 FUJIFILM Diosynth Biotechnologies U.S.A. Business Overview
    • 11.1.3 FUJIFILM Diosynth Biotechnologies U.S.A. Genetic Virus Vector Introduction
    • 11.1.4 FUJIFILM Diosynth Biotechnologies U.S.A. Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.1.5 FUJIFILM Diosynth Biotechnologies U.S.A. Recent Development
  • 11.2 Sanofi
    • 11.2.1 Sanofi Company Details
    • 11.2.2 Sanofi Business Overview
    • 11.2.3 Sanofi Genetic Virus Vector Introduction
    • 11.2.4 Sanofi Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.2.5 Sanofi Recent Development
  • 11.3 Lonza
    • 11.3.1 Lonza Company Details
    • 11.3.2 Lonza Business Overview
    • 11.3.3 Lonza Genetic Virus Vector Introduction
    • 11.3.4 Lonza Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.3.5 Lonza Recent Development
  • 11.4 Merck KGaA
    • 11.4.1 Merck KGaA Company Details
    • 11.4.2 Merck KGaA Business Overview
    • 11.4.3 Merck KGaA Genetic Virus Vector Introduction
    • 11.4.4 Merck KGaA Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.4.5 Merck KGaA Recent Development
  • 11.5 GENERAL ELECTRIC COMPANY
    • 11.5.1 GENERAL ELECTRIC COMPANY Company Details
    • 11.5.2 GENERAL ELECTRIC COMPANY Business Overview
    • 11.5.3 GENERAL ELECTRIC COMPANY Genetic Virus Vector Introduction
    • 11.5.4 GENERAL ELECTRIC COMPANY Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.5.5 GENERAL ELECTRIC COMPANY Recent Development
  • 11.6 Oxford BioMedica
    • 11.6.1 Oxford BioMedica Company Details
    • 11.6.2 Oxford BioMedica Business Overview
    • 11.6.3 Oxford BioMedica Genetic Virus Vector Introduction
    • 11.6.4 Oxford BioMedica Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.6.5 Oxford BioMedica Recent Development
  • 11.7 Spark Therapeutics, Inc.
    • 11.7.1 Spark Therapeutics, Inc. Company Details
    • 11.7.2 Spark Therapeutics, Inc. Business Overview
    • 11.7.3 Spark Therapeutics, Inc. Genetic Virus Vector Introduction
    • 11.7.4 Spark Therapeutics, Inc. Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.7.5 Spark Therapeutics, Inc. Recent Development
  • 11.8 uniQure N.V.
    • 11.8.1 uniQure N.V. Company Details
    • 11.8.2 uniQure N.V. Business Overview
    • 11.8.3 uniQure N.V. Genetic Virus Vector Introduction
    • 11.8.4 uniQure N.V. Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.8.5 uniQure N.V. Recent Development
  • 11.9 FinVector Vision Therapies
    • 11.9.1 FinVector Vision Therapies Company Details
    • 11.9.2 FinVector Vision Therapies Business Overview
    • 11.9.3 FinVector Vision Therapies Genetic Virus Vector Introduction
    • 11.9.4 FinVector Vision Therapies Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.9.5 FinVector Vision Therapies Recent Development
  • 11.10 Brammer Bio
    • 11.10.1 Brammer Bio Company Details
    • 11.10.2 Brammer Bio Business Overview
    • 11.10.3 Brammer Bio Genetic Virus Vector Introduction
    • 11.10.4 Brammer Bio Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.10.5 Brammer Bio Recent Development
  • 11.11 Cell and Gene Therapy Catapult
    • 11.11.1 Cell and Gene Therapy Catapult Company Details
    • 11.11.2 Cell and Gene Therapy Catapult Business Overview
    • 11.11.3 Cell and Gene Therapy Catapult Genetic Virus Vector Introduction
    • 11.11.4 Cell and Gene Therapy Catapult Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.11.5 Cell and Gene Therapy Catapult Recent Development
  • 11.12 Cobra Biologics
    • 11.12.1 Cobra Biologics Company Details
    • 11.12.2 Cobra Biologics Business Overview
    • 11.12.3 Cobra Biologics Genetic Virus Vector Introduction
    • 11.12.4 Cobra Biologics Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.12.5 Cobra Biologics Recent Development
  • 11.13 REGENXBIO Inc.
    • 11.13.1 REGENXBIO Inc. Company Details
    • 11.13.2 REGENXBIO Inc. Business Overview
    • 11.13.3 REGENXBIO Inc. Genetic Virus Vector Introduction
    • 11.13.4 REGENXBIO Inc. Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.13.5 REGENXBIO Inc. Recent Development
  • 11.14 Kaneka Eurogentec S.A.
    • 11.14.1 Kaneka Eurogentec S.A. Company Details
    • 11.14.2 Kaneka Eurogentec S.A. Business Overview
    • 11.14.3 Kaneka Eurogentec S.A. Genetic Virus Vector Introduction
    • 11.14.4 Kaneka Eurogentec S.A. Revenue in Genetic Virus Vector Business (2016-2021)
    • 11.14.5 Kaneka Eurogentec S.A. Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Genetic Virus Vector Scope and Market Size
    Genetic Virus Vector market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Genetic Virus Vector market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Retroviral Vectors
    Adenoviral Vectors
    Adeno-Associated Viral Vectors
    Other

    Segment by Application
    Gene Therapy
    Vaccinology

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    FUJIFILM Diosynth Biotechnologies U.S.A.
    Sanofi
    Lonza
    Merck KGaA
    GENERAL ELECTRIC COMPANY
    Oxford BioMedica
    Spark Therapeutics, Inc.
    uniQure N.V.
    FinVector Vision Therapies
    Brammer Bio
    Cell and Gene Therapy Catapult
    Cobra Biologics
    REGENXBIO Inc.
    Kaneka Eurogentec S.A.

    Buy now